Literature DB >> 15936213

Erythropoietin promotes regeneration of adult CNS neurons via Jak2/Stat3 and PI3K/AKT pathway activation.

Alexandra Kretz1, Caroline J Happold, Julia K Marticke, Stefan Isenmann.   

Abstract

The cytokine hormone erythropoietin (EPO) has proved neuroprotective in CNS injury, and clinical trials for ischemic stroke are ongoing. The capability of EPO to restore postmitotic CNS architecture and function by fibre regeneration has not been examined. Here, we compared in vitro outgrowth capacity of adult retinal ganglion cells (RGCs) following optic nerve (ON) lesion in the presence and absence of EPO. Immediate EPO conditioning in vivo, or delayed EPO treatment of cultures with 10--10,000 IU rhEPO significantly increased numbers (2.66-fold) and length (8.31-fold) of newly generated neurites, without evoking rheological complications. EPO induced Stat3 phosphorylation in RGCs, and inhibition of Jak2/Stat3 abolished EPO-induced growth. EPO-facilitated neuritogenesis was paralleled by upregulation of Bcl-X(L), a Bcl-2 homologue capable of promoting RGC regeneration. The PI3K/Akt pathway was also involved in antiapoptotic and regeneration-enhancing EPO actions. In conclusion, EPO treatment may offer a unique dual-function strategy for neuroprotection and regeneration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15936213     DOI: 10.1016/j.mcn.2005.04.009

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  59 in total

1.  Latanoprost promotes neurite outgrowth in differentiated RGC-5 cells via the PI3K-Akt-mTOR signaling pathway.

Authors:  Jun Zheng; Xuemei Feng; Lina Hou; Yongyao Cui; Liang Zhu; Jian Ma; Zheng Xia; Wei Zhou; Hongzhuan Chen
Journal:  Cell Mol Neurobiol       Date:  2011-01-29       Impact factor: 5.046

2.  Dose-dependent treatment of optic nerve crush by exogenous systemic mutant erythropoietin.

Authors:  Timothy A Sullivan; Eldon E Geisert; Justin P Templeton; Tonia S Rex
Journal:  Exp Eye Res       Date:  2012-01-27       Impact factor: 3.467

3.  Erythropoietin Attenuates the Apoptosis of Adult Neurons After Brachial Plexus Root Avulsion by Downregulating JNK Phosphorylation and c-Jun Expression and Inhibiting c-PARP Cleavage.

Authors:  Kai Li; Rang-Juan Cao; Xiao-Juan Zhu; Xing-Yu Liu; Long-Yun Li; Shu-Sen Cui
Journal:  J Mol Neurosci       Date:  2015-04-16       Impact factor: 3.444

4.  Therapeutic strategies for the inherited neuropathies.

Authors:  Michael E Shy
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

5.  Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.

Authors:  Srdan Verstovsek; Constantine S Tam; Martha Wadleigh; Lubomir Sokol; Catherine C Smith; Lynne A Bui; Chunyan Song; Douglas O Clary; Patrycja Olszynski; Jorge Cortes; Hagop Kantarjian; Neil P Shah
Journal:  Leuk Res       Date:  2013-12-11       Impact factor: 3.156

6.  Effect of Recombinant Human Erythropoietin On the Stemness of Bone Marrow-derived Mesenchymal Stem Cells in vitro.

Authors:  Lihua Ye; Long Chen; Qiang Yu; Fanjun Cheng
Journal:  Int J Stem Cells       Date:  2010-05       Impact factor: 2.500

7.  Enhanced survival of melanopsin-expressing retinal ganglion cells after injury is associated with the PI3 K/Akt pathway.

Authors:  Suk-Yee Li; Suk-Yu Yau; Bai-Yu Chen; David K Tay; Vincent W H Lee; Ming-Liang Pu; Henry H L Chan; Kwok-Fai So
Journal:  Cell Mol Neurobiol       Date:  2008-05-30       Impact factor: 5.046

8.  [New aspects in the therapy of multiple sclerosis and optic neuritis].

Authors:  W Lagrèze; R Diem
Journal:  Ophthalmologe       Date:  2014-08       Impact factor: 1.059

Review 9.  Role of signal transducer and activator of transcription 3 in neuronal survival and regeneration.

Authors:  Suzan Dziennis; Nabil J Alkayed
Journal:  Rev Neurosci       Date:  2008       Impact factor: 4.353

10.  Imatinib induces apoptosis by inhibiting PDGF- but not insulin-induced PI 3-kinase/Akt survival signaling in RGC-5 retinal ganglion cells.

Authors:  Swarajit K Biswas; Yan Zhao; Lakshman Sandirasegarane
Journal:  Mol Vis       Date:  2009-08-15       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.